<DOC>
	<DOC>NCT00240578</DOC>
	<brief_summary>This is a multi-center study for the long-term follow-up of surviving patients who are expected to complete or who have completed at least two years of follow-up after treatment with Iodine I 131 Tositumomab (BEXXAR) on Studies CP-97-011, CP-98-025, CP-99-032, or CP-99-036. All patients will be assessed for survival and disease status, including subsequent therapy for NHL, and for long-term safety. Additionally Laboratory evaluations consisting of a TSH level and a complete blood cell (CBC) count with a differential and platelet count will be obtained annually. Additionally, patients who remain in long-term response following Iodine I 131 Tositumomab treatment will be followed for response and progression.</brief_summary>
	<brief_title>Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Iodine I 131 Tositumomab</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Iodine-131 anti-B1 antibody</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<criteria>Patients must have enrolled in one of the following Corixa sponsored clinical trials: CP97011, CP98025, CP99032, or CP99036 and are &gt;2 years post treatment with Iodine I 131 Tositumomab. Patients must give written informed consent by signing an IRB/ethics committee approved consent form prior to entry on this followup study. Inability to meet above referenced inclusion criteria.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Long-Term Follow-up</keyword>
	<keyword>BEXXAR</keyword>
	<keyword>Iodine I 131 Tositumomab</keyword>
	<keyword>Low-grade lymphoma</keyword>
</DOC>